Web Research
What the Internet Knows About Onyx Biotec
Figures converted from INR at historical FX rates — see data/company.json.fx_rates for the rate table. Ratios, margins, and multiples are unitless and unchanged.
The Bottom Line from the Web
Onyx Biotec's first full year as a public company (FY26) reversed the IPO narrative: revenue grew ~12% to $7.41M, but the company swung from a $0.58M PAT in FY25 to a $0.02M net loss in FY26 — and the stock now trades at $0.33, roughly 48% below its November 2024 issue price of $0.73. The most consequential web-only finding is the September 18, 2025 bulk-deal exit of anchor investor Zeta Global Funds (374,000 shares at ~$0.51) followed by a board reshuffle in 2025 that installed Sanjay Jain as MD and Harsh Mahajan as CFO/Whole-Time Director — signals you cannot see in the FY25 annual report alone.
Triple red flag combination: (1) anchor investor exited at ~$0.51 in Sept 2025 — well below issue but well above today's $0.33; (2) FY26 swung to a loss after FY25's profit; (3) the IPO objects include $1.43M of promoter-linked debt repayment, and Unit I LVP upgrade timing is opaque in public disclosure. Each is survivable; together they explain the 48% post-listing drawdown.
What Matters Most
IPO Price ($)
Listing Price ($)
Current Price ($) – 20 May 2026
Drawdown from IPO
1. FY26 swung to a loss despite revenue growth
Onyx Biotec reported a net loss of approximately $22.9K for the full year ended March 31, 2026, reversing FY25's PAT of approximately $0.58M, even as revenue from operations grew from $7.25M to $7.41M (+12% in INR; flat-to-marginal in USD due to FX drag). Total expenditure surged from $6.63M to $7.50M (+13% in USD; +24% in INR). Results were approved at the Board meeting on May 14, 2026. Source: scanx.trade.
Q4 FY26 standalone PAT was approximately $0.11M per Univest, implying H1 FY26 carried the bulk of the loss — consistent with margin compression while Unit II ramps and the high-cost cephalosporin API cycle bites. The 24% INR expenditure jump on 12% INR revenue growth is the single most material number for FY26 that is not visible from the FY25 prospectus.
2. Anchor investor exited 10 months after listing
Zeta Global Funds (OEIC) PCC Limited — Zeta Series B Fund PC sold 374,000 shares on September 18, 2025 at approximately $0.51 per share per the Goodreturns bulk-deal log. This is the anchor allocation walking out of a Tier-2 NSE SME name once the standard six-month lock-in expired. On the same date, Prognosis Securities purchased 100,000 shares — a far smaller offset.
The exit price of ~$0.51 is itself 30% below the $0.73 issue. Today's $0.33 print means anyone who bought from Zeta in September 2025 is down another ~35% in eight months. This is the kind of post-lock-in distribution signal that no filing summary will surface.
3. Promoter-family bulk deal at depressed prices (March 2026)
On March 24, 2026, Deepak Baid (HUF) bought 150,000 shares at approximately $0.310 and Deepak Baid (individual) sold 150,000 shares at approximately $0.310 (Goodreturns) — a near-perfect internal transfer at a price 57% below the IPO. On March 30, 2026 a single bulk deal moved 350,000 shares at approximately $0.342 (Trendlyne).
The individual-to-HUF transfer is a common Indian tax/estate-planning move and is not, on its own, a red flag, but the fact that it is the most visible insider activity post-listing (rather than open-market buying at depressed prices) is itself a tell.
4. Board reshuffle in 2025 added two executive roles
Per BlinkX board insights: "Sanjay Jain joins the board as Executive Director & MD, in a new position in 2025" and "Harsh Mahajan joins the board as Executive Director / Whole Time Director / CFO, in a new position in 2025." These are new executive roles created post-listing — i.e., the leadership structure that pitched the IPO is not the structure now running the company.
Sanjay Jain is one of the three named promoters (with Naresh Kumar and Fateh Pal Singh) per Upstox, so the MD role formalises promoter control rather than imports outside talent. Lakshya Jain is listed as Whole Time Director — same surname as Sanjay Jain, but the public record does not explicitly state the family relationship (specialist query Q29). The Naresh Kumar–Lakshya Jain–Sanjay Jain trio plus Paramjeet Kaur (Non-Executive, Non-Independent) is a tight promoter-family board (onyxbiotec.com/our-management).
5. IPO proceeds and Unit I LVP upgrade — no completion confirmation yet
The IPO objects per Investorzone and AliceBlue were: (i) upgradation of Unit I to manufacture Large Volume Parenterals (LVP) for intravenous use; (ii) high-speed cartoning packaging line at Unit II for DPI; (iii) $1.43M for repayment of borrowings; (iv) general corporate purposes — totalling ~$3.50M. Eighteen months after listing, public search yields no investor presentation, no LVP-commissioning press release, and no Unit I shipment confirmation. SEBI's NSE EMERGE circular (effective September 5, 2024) requires statutory-auditor-certified utilization disclosure each half-year (MMJC) — meaning Onyx is required to file these, but search did not surface a deviation notice. Treat the absence of LVP-go-live news as a watch item, not a confirmed delay.
6. Simply Wall St flagged debt risk
Simply Wall St published "We Think Onyx Biotec (NSE:ONYX) Is Taking Some Risk With Its Debt" — title alone is the signal (Simply Wall St). The bulk of IPO proceeds were earmarked for capex, not deleveraging; only $1.43M (~41% of the issue) was for debt repayment.
7. The "Tier-2 growth player" framing — analyst consensus is thin and qualified
The most substantive analyst-style framing comes from Bitget's ONYX profile: "Onyx Biotec is currently positioned as a Tier-2 growth player in the Indian injectable space. While it does not yet have the global scale of giants like Gland Pharma, its specialization in the 'essentials' (sterile water, cephalosporin DPIs) is its core strength… A significant portion of Onyx Biotec's revenue is derived from a handful of large pharmaceutical clients. Analysts warn that any change in procurement strategy or insourcing by these major players could materially impact Onyx's top-line growth." No sell-side broker has published a price target reachable via search. Trendlyne flags a 42.86% fall from the 52-week high (Trendlyne) — and lists the stock under its "significant over 30% distance from 52-week high" screener.
8. Customer concentration: 35 of 100+ clients drive the repeat business
Per MarketsGuruji and Zerodha IPO note: "During the Financial Year 2024, we manufactured for more than 100 leading pharmaceutical companies. Furthermore, we have benefitted from repeat orders in the past three years from 35 of our more than 100 clients in terms of revenue." Named clients in external press: Mankind Pharma, Sun Pharmaceutical Industries (Bitget). The unspecified "top 5" share has not been disclosed publicly post-IPO — specialist query Q0/Q8 searched extensively and found no quantification beyond the "35 repeat clients" line.
9. Galpha Laboratories partnership
MarketScreener reported Onyx Biotec entered a contract-manufacturing agreement with Galpha Laboratories — a notable mid-tier Indian pharma player. This is the kind of customer-addition news that supports the "repeat client + new client" narrative but does not, by itself, override the FY26 P&L deterioration.
10. Geographic single-point-of-failure flagged in IPO docs
Both units are in Solan, Himachal Pradesh. Per Enrichmoney IPO note: "This concentration means that any unfavorable changes in the regional business environment could significantly impact the company's operations and overall prospects." Standard small-CDMO risk language but worth flagging given the FY26 cost shock.
Recent News Timeline
What the Specialists Asked
Governance and People Signals
Board composition (per Onyx Biotec Our Management and BlinkX)
Notable insider / bulk-deal transactions
Sources: Goodreturns bulk deals, Trendlyne bulk-block deals.
Pattern: Anchor walked at the first opportunity (Sept 2025, ~$0.51 — a 30% loss for them but still well above today's $0.33). Subsequent visible insider activity has been intra-family (Deepak Baid → Deepak Baid HUF) rather than open-market accumulation by promoters at the trough. No promoter buying in size at $0.29–0.34 is itself a soft negative tell.
Industry Context
The sterile-injectables outsourcing thesis is structurally sound — half of pharma demand is addressable and the capex barrier is high — but Onyx is a sub-scale participant in a market where Gland Pharma, Caplin Point, Akums, and Nectar Lifesciences command tens-of-times the revenue and the cost-curve advantages that come with that. The PLI scheme supports the segment but is not Onyx-specific, and most allocations have flowed to larger players (Bitget).
The most useful industry read-through: 57% outsourcing of sterile injectables + US$300M+ aseptic-line build cost describe a market that protects incumbents, not new entrants. Onyx benefits from the outsourcing trend but does not have the scale to win share from larger CDMOs unless it executes flawlessly on Unit II ramp and the Unit I LVP upgrade. FY26's miss makes that execution case harder to underwrite.